Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kintor PharmaceuticalKNTPF 28 EV-to-OCF is -5.08 as of Aug. 13, 2026. GuruFocus rates KNTPF with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Kintor Pharmaceutical ranks better than 56.75% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Kintor Pharmaceutical's Enterprise Value is $121.54 Mil.
Kintor Pharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-23.91 Mil. Therefore, Kintor Pharmaceutical's EV-to-OCF for today is -5.08.
The historical rank and industry rank for Kintor Pharmaceutical's EV-to-OCF or its related term are showing as below:
KNTPF'
s EV-to-OCF Range Over the Past 10 Years
Min: -222.35 Med: -3.33 Max: 0.61
Current: -5.08
During the past 8 years, the highest EV-to-OCF of Kintor Pharmaceutical was 0.61. The lowest was -222.35. And the median was -3.33.
KNTPF's EV-to-OCF is ranked better than 56.75% of 1408
companies
in the Biotechnology industry
Industry Median: -3.53
vs KNTPF: -5.08
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Kintor Pharmaceutical's PE Ratio (TTM) for today is calculated as:
Kintor Pharmaceutical's share price for today is $0.2399.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.061.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Kintor Pharmaceutical's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kintor Pharmaceutical EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kintor Pharmaceutical's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Kintor Pharmaceutical's EV-to-OCF falls into.
Kintor Pharmaceutical's current Enterprise Value is $121.54 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Kintor Pharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-23.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kintor Pharmaceutical (KNTPF) has a EV-to-OCF of -5.08 as of Aug. 13, 2026. According to the industry distribution chart, Kintor Pharmaceutical ranks #609 out of 1408 companies in the Biotechnology industry, placing it in the top 43.3%.
Is Kintor Pharmaceutical's EV-to-OCF too high?
Kintor Pharmaceutical's current EV-to-OCF is -5.08. Based on the distribution chart, Kintor Pharmaceutical ranks #609 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Kintor Pharmaceutical has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Kintor Pharmaceutical ranks #609 out of 1408 companies for EV-to-OCF. This puts Kintor Pharmaceutical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Kintor Pharmaceutical's current EV-to-OCF is -5.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current EV-to-OCF of -5.08. The current EV-to-OCF is -5.08. Kintor Pharmaceutical's overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current EV-to-OCF is -5.08 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
28GF Score
Get the complete analysis for KNTPF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNTPF has been successfully added to your 
